# Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

> **NCT02379091** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 108 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Namilumab
- **DRUG:** Placebo
- **DRUG:** Methotrexate
- **DRUG:** Folic/folinic acid

## Key facts

- **NCT ID:** NCT02379091
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-17
- **Primary completion:** 2016-05-11
- **Final completion:** 2016-12-05
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02379091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02379091, "Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02379091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*